Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 1, Pages e000326
Publisher
BMJ
Online
2020-03-18
DOI
10.1136/jitc-2019-000326
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
- (2019) Wenting Liao et al. CANCER CELL
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Contribution of Epithelial Plasticity to Therapy Resistance
- (2019) Patricia G. Santamaría et al. Journal of Clinical Medicine
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
- (2018) Michael Carleton et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Pembrolizumab in Combination with Ipilimumab as Second-Line or Later Therapy for Advanced Non–Small-Cell Lung Cancer: KEYNOTE-021 Cohorts D and H
- (2018) M.A. Gubens et al. LUNG CANCER
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
- (2017) Caroline Jochems et al. Oncotarget
- Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis
- (2017) Keiichi Asano et al. Scientific Reports
- A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
- (2017) Justin M. David et al. OncoImmunology
- Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
- (2017) Rahima Jamal et al. Journal for ImmunoTherapy of Cancer
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
- (2016) Y. Lou et al. CLINICAL CANCER RESEARCH
- PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
- (2016) Chan-Young Ock et al. Oncotarget
- IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
- (2016) Romaine I. Fernando et al. Oncotarget
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
- (2015) G. K. Pennock et al. ONCOLOGIST
- Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment
- (2015) ZI WANG et al. ONCOLOGY REPORTS
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- TGF-β Activation and Function in Immunity
- (2013) Mark A. Travis et al. Annual Review of Immunology
- Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
- (2011) Suling Liu et al. CANCER RESEARCH
- IL-8 Signaling Plays a Critical Role in the Epithelial-Mesenchymal Transition of Human Carcinoma Cells
- (2011) R. I. Fernando et al. CANCER RESEARCH
- CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
- (2010) Christophe Ginestier et al. JOURNAL OF CLINICAL INVESTIGATION
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epithelial-Mesenchymal Transitions in Development and Disease
- (2009) Jean Paul Thiery et al. CELL
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- The Interleukin-8 Pathway in Cancer
- (2008) D. J.J. Waugh et al. CLINICAL CANCER RESEARCH
- Tumor-derived TGF-β Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas Cancer
- (2008) Tricia A. Moo-Young et al. JOURNAL OF IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started